Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2018-000428-32 | EudraCT Number | ||
| 64264681EDI1003 | Other Identifier | Janssen Research & Development, LLC |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The primary purpose of this study is to investigate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of JNJ-64264681 in healthy participants after single and multiple oral doses.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Single Ascending Dose (SAD) | Experimental | The SAD part will consist of 6 escalating dose cohorts and 1 fed cohort of healthy male participants, 2 dose escalating cohorts of healthy female participants, and 1 solid dose formulation (capsule) cohort of healthy male participants, who will be dosed after completion of the dose escalation cohorts. Participants in each cohort (except for the solid dose formulation cohort) will receive JNJ-64264681 or Placebo on Day 1, orally. In the solid dose formulation cohort, participants will receive JNJ-64264681 capsule on Day 1. Doses for the female cohorts and fed cohort will be selected based on safety, tolerability, pharmacokinetics (PK),and pharmacodynamic (PD) data from preceding cohorts and the dose for the solid dose formulation cohort will be selected and approximately equal to a dose previously studied in the single ascending dose cohorts. |
|
| Multiple Ascending Dose (MAD) | Experimental | The MAD part will consist of 3 dose escalation cohorts of males and females. Participants will receive once-daily oral doses of JNJ-64264681 or placebo for 10 consecutive days. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| JNJ-64264681 | Drug | For all cohorts except the solid dose formulation cohort, JNJ-64264681 wlll be administered as oral solution. For the solid dose formulation cohort, JNJ-64264681 will be provided as capsules for oral administration. |
| Measure | Description | Time Frame |
|---|---|---|
| Single Ascending Dose (SAD): Number of Participants with Adverse Events | An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. | Up to Day 14 |
| Multiple Ascending Dose (MAD): Number of Participants with Adverse Events | An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. | Up to Day 24 |
| SAD: Maximum Observed Plasma Concentration (Cmax) | Cmax is the maximum observed plasma JNJ-64264681 concentration. | Up to Day 4 |
| MAD: Maximum Observed Plasma Concentration (Cmax) | Cmax is the maximum observed plasma JNJ-64264681 concentration. | Up to Day 13 |
| SAD: Time to Reach Maximum Observed Plasma Concentration (Tmax) | Tmax is defined as actual sampling time to reach maximum observed concentration. | Up to Day 4 |
| MAD: Time to Reach Maximum Observed Plasma Concentration (Tmax) | Tmax is defined as actual sampling time to reach maximum observed concentration. | Up to Day 13 |
| SAD: Time to Last Quantifiable Plasma Concentration (Tlast) |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Janssen Research & Development, LLC Clinical Trial | Janssen Research & Development, LLC | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Clinical Pharmacology Unit | Merksem | 2170 | Belgium |
Not provided
| ID | Term |
|---|---|
| C000729293 | JNJ-64264681 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo | Drug | Matching placebo to JNJ-64264681 will be administered as oral solution. |
|
The Tlast is the time to last observed quantifiable plasma concentration. |
| Up to Day 4 |
| MAD: Time to Last Quantifiable Plasma Concentration (Tlast) | The Tlast is the time to last observed quantifiable plasma concentration. | Up to Day 13 |
| SAD: Area Under the Plasma Concentration-time Curve From Time Zero to 24 Hours (AUC[0-24]) | AUC (0-24) is the area under the plasma concentration-time curve from time zero to 24 hours. | Day 1: Up to 24 hours post-dose |
| MAD: Area Under the Plasma Concentration-time Curve From Time Zero to 24 Hours (AUC[0-24]) | AUC (0-24) is the area under the plasma concentration-time curve from time zero to 24 hours. | Day 1: Up to 24 hours post-dose |
| SAD: Area Under the Plasma Concentration-time Curve From Time 0 to Time of the Last Observed Quantifiable Concentration (AUClast) | AUClast is defined as area under the plasma JNJ-64264681 concentration-time curve from time 0 to time of the last observed quantifiable concentration. | Up to Day 4 |
| MAD: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) | AUCtau is area under the plasma JNJ-64264681 concentration-time curve during a dosing interval (tau) at steady-state. | Day 10 |
| SAD: Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC[0-infinity]) | The AUC (0-infinity) is the area under the plasma concentration-time curve from time zero to infinite time, calculated as the sum of AUC(last) and C(last)/lambda(z); wherein AUC(last) is area under the plasma concentration-time curve from time zero to last quantifiable time, C(last) is the last observed quantifiable concentration, and lambda(z) is elimination rate constant. | Up to Day 3 |
| SAD: Apparent Elimination Half-life (t1/2) | t1/2 is apparent elimination half-life of JNJ-64264681 associated with the terminal slope (z) of the semi-logarithmic drug concentration-time curve. | Up to Day 3 |
| MAD: Apparent Elimination Half-life (t1/2) | t1/2 is apparent elimination half-life of JNJ-64264681 associated with the terminal slope (z) of the semi-logarithmic drug concentration-time curve. | Up to Day 13 |
| MAD: Accumulation Ratio | MAD: Accumulation Ratio obtained by dividing AUC of JNJ-64264681 at two different time points. | Up to Day 13 |